Table 1.
Tumor-initiating capacity of unsorted pancreatic adenocarcinoma, lung adenocarcinoma, squamous cell lung carcinoma, and head/neck squamous cell carcinoma cells in NOD/SCID and NSG mice. The TIC frequency was calculated using a limiting dilution analysis (Hu and Smyth, 2009) or L-Calc Software (Stem Cell Technologies) (with 95% confidence intervals) and significance determined by chi-squared analysis. See also Table S1 for TIC frequencies in subcutaneous versus orthotopic injections and primary versus high-passage human non-small cell lung cancer xenografts.
| Tumor formation | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tumor Type | Case # | Mouse Strain | 106 | 105 | 3×104 | 104 | 5×103 | 103 | 5×102 | 102 | TIC frequency−1 (95% CI) | P- value |
| Pancreatic adenocarcinoma | Panc253 | NSG | - | - | - | - | 2/4 | 1/4 | 0/4 | - | 6,600 (2,100–21,000) | 0.19 |
| NOD/SCID | - | - | - | - | 4/4 | 1/4 | 0/4 | - | 2,500 (980–6,200) | |||
| Panc219 | NSG | - | - | - | - | 4/4 | 1/4 | 0/4 | - | 2,500 (980–6,200) | 0.48 | |
| NOD/SCID | - | - | - | - | 3/4 | 1/4 | 0/4 | - | 4,100 (1500–11,000) | |||
| Panc140 | NSG | - | - | - | - | 1/3 | 0/4 | 0/4 | - | 18,000 (2,700–127,000) | 0.47 | |
| NOD/SCID | - | - | - | - | 2/3 | 0/4 | 0/4 | - | 7,700 (2,000–30,000) | |||
| Lung adenocarcinoma | ADC1 | NSG | - | - | - | 2/4 | - | 0/4 | - | - | 16,000 (4,000–68,000) | - |
| NOD/SCID | - | 0/4 | - | 0/4 | - | 0/6 | - | - | >100,000 (-) | |||
| ADC2 | NSG | - | - | - | 2/4 | - | 0/4 | - | - | 16,000 4,000–68,000 |
0.28 | |
| NOD/SCID | - | 4/4 | - | 0/4 | - | 0/4 | - | - | 43,000 14,000–131,000 |
|||
| ADC3 | NSG | - | - | 2/4 | 2/4 | - | 0/4 | - | 0/4 | 30,000 18,000–80,000 |
.62 | |
| NOD/SCID | - | 4/4 | - | 0/4 | - | 0/4 | - | - | 43,000 14,000–131,000 |
|||
| Squamous cell lung carcinoma | SCC1 | NSG | - | - | - | 4/4 | - | 0/4 | - | - | 4,200 1,400–13,000 |
0.002 |
| NOD/SCID | - | 2/3 | - | 2/4 | - | 0/4 | - | - | 51,000 15,000–172,000 |
|||
| SCC2 | NSG | - | - | - | 2/4 | - | 0/4 | - | - | 16,000 4,000–68,000 |
0.03 | |
| NOD/SCID | - | 1/4 | - | 2/4 | - | 0/4 | - | - | 125,000 34,000–453,000 |
|||
| SCC3 | NSG | - | - | - | 3/4 | - | 2/4 | - | - | 4,600 1,500–14,000 |
0.003 | |
| NOD/SCID | - | 5/6 | - | 2/4 | - | 0/4 | - | - | 42,000 16,000–108,000 |
|||
| Head/Neck squamous cell carcinoma | HN1 | NSG | 3/3 | 3/3 | - | 2/3 | - | 1/3 | - | 0/6 | 6,900 1,900–25,000 |
0.07 |
| NOD/SCID | 3/3 | 2/3 | - | 2/3 | - | 1/3 | - | 0/6 | 36,000 10,000–133,000 |
|||
| HN2 | NSG | - | 2/3 | - | 2/3 | - | 1/3 | - | 0/4 | 36,000 19,000–70,000 |
0.78 | |
| NOD/SCID | - | 2/3 | - | 2/3 | - | 0/3 | - | 0/4 | 48,000 13,000–170,000 |
|||
| HN3 | NSG | - | 5/5 | - | 5/5 | - | 0/5 | - | 0/5 | 4,300 1,600–11,600 |
0.67 | |
| NOD/SCID | - | 5/5 | - | 3/5 | - | 3/5 | - | 0/5 | 5,800 2,100–15,600 |
|||